Aadi Bioscience (NASDAQ:AADI) Posts Quarterly Earnings Results, Misses Estimates By $0.36 EPS

Aadi Bioscience (NASDAQ:AADI) posted its quarterly earnings results on Tuesday. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.36), Zacks reports. Aadi Bioscience had a negative net margin of 246.06% and a negative return on equity of 71.87%.

Aadi Bioscience Stock Performance

Shares of NASDAQ AADI traded down $0.04 during trading on Tuesday, hitting $2.06. 49,245 shares of the company were exchanged, compared to its average volume of 244,689. The company has a fifty day moving average price of $2.73 and a 200-day moving average price of $2.40. The firm has a market capitalization of $50.80 million, a PE ratio of -0.90 and a beta of 0.68. Aadi Bioscience has a 12-month low of $1.21 and a 12-month high of $3.81.

Aadi Bioscience Company Profile

Aadi Bioscience, Inc, a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa.